Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy

Chimeric antigen receptor (CAR) T cells targeting CD19(+) B cells have demonstrated efficacy in refractory systemic lupus erythematosus (SLE). Although initial clinical data suggest that anti-CD19 CAR T cell therapy is well tolerated and highly effective, the immunologic consequences of CAR T cell t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nunez, Daniel, Patel, Darshil, Volkov, Jenell, Wong, Steven, Vorndran, Zachary, Müller, Fabian, Aigner, Michael, Völkl, Simon, Mackensen, Andreas, Schett, Georg, Basu, Samik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514439/
https://www.ncbi.nlm.nih.gov/pubmed/37744005
http://dx.doi.org/10.1016/j.omtm.2023.08.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514439/
https://www.ncbi.nlm.nih.gov/pubmed/37744005
http://dx.doi.org/10.1016/j.omtm.2023.08.023

Ejemplares similares